AR and prostate carcinoma: In another study, the combination of enzalutamide and navitoclax (ABT-263) increased sensitivity in both enzalutamide-sensitive and (primary and acquired) -resistant prostate cancer cells, with elevated proteasomal degradation of AR and AR splice variant 7 (AR-V7) [218].